Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: The tumor necrosis factor-α inhibitors infliximab and adalimumab are standard treatments for moderate to severe ulcerative colitis (UC). However, there has been no headto- head comparison of treatment efficacy and outcomes between the two agents. The aim of this study was to compare the efficacy and long-term outcomes of infliximab versus adalimumab treatment in biologic-naïve patients with UC. Methods: We retrospectively analyzed the records of 113 biologic-naïve patients with UC who were treated between September 2012 and December 2017 (the infliximab group [n=83] and the adalimumab group [n=30]). We compared remission and response rates between these groups at 8 and 52 weeks. We used Kaplan-Meier curves to compare long-term outcomes, and logistic regression analysis and Cox-proportional hazard regression models to assess factors affecting outcomes. Results: The median follow-up duration was 25.8 months. Baseline clinical characteristics were similar between groups. There were no significant differences between the two groups in the rate of clinical remission or clinical response at 8 or 52 weeks. Multivariate analyses also showed that long-term outcomes were not significantly different (adjusted hazard ratio [HR], 1.45; 95% confidence interval [CI], 0.81 to 2.56; p=0.208). An elevated C-reactive protein level (greater than 5 mg/L) was a significant predictive factor for poor outcomes (adjusted HR, 2.25; 95% CI, 1.37 to 3.70; p=0.001). During the follow-up period, the rates of adverse event were not significantly different between the two groups (p=0.441). Conclusions: In our study, infliximab and adalimumab had similar treatment efficacy and longterm outcomes in biologic-naïve patients with moderate to severe UC.
Abstract
Background/Aims: The tumor necrosis factor-α inhibitors infliximab and adalimumab are standard treatments for moderate to severe ulcerative colitis (UC). However, there has been no headto- head comparison of treatment efficacy and outcomes between the two agents. The aim of this study was to compare the efficacy and long-term outcomes of infliximab versus adalimumab treatment in biologic-naïve patients with UC. Methods: We retrospectively analyzed the records of 113 biologic-naïve patients with UC who were treated between September 2012 and December 2017 (the infliximab group [n=83] and the adalimumab group [n=30]). We compared remission and response rates between these groups at 8 and 52 weeks. We used Kaplan-Meier curves to compare long-term outcomes, and logistic regression analysis and Cox-proportional hazard regression models to assess factors affecting outcomes. Results: The median follow-up duration was 25.8 months. Baseline clinical characteristics were similar between groups. There were no significant differences between the two groups in the rate of clinical remission or clinical response at 8 or 52 weeks. Multivariate analyses also showed that long-term outcomes were not significantly different (adjusted hazard ratio [HR], 1.45; 95% confidence interval [CI], 0.81 to 2.56; p=0.208). An elevated C-reactive protein level (greater than 5 mg/L) was a significant predictive factor for poor outcomes (adjusted HR, 2.25; 95% CI, 1.37 to 3.70; p=0.001). During the follow-up period, the rates of adverse event were not significantly different between the two groups (p=0.441). Conclusions: In our study, infliximab and adalimumab had similar treatment efficacy and longterm outcomes in biologic-naïve patients with moderate to severe UC.
참고문헌 (38)
- Adams SM, "Ulcerative colitis", Am Fam Physician, 87, pp.699~705 (2013)
- Reinisch W, "Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis : results of a randomised controlled trial", Gut, 60, pp.780~787 (2011)
- Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis", N Engl J Med, 353, pp.2462~2476 (2005)
- Sandborn WJ, "Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis", Gastroenterology, 142, pp.257~265 (2012)
- Tomohiro Fukuda, "Current new challenges in the management of ulcerative colitis", Intestinal research, 17(1), pp.36~44 (2019), 대한장연구학회[DOI]
- Salleron J, "Effectiveness research in inflammatory bowel disease : a necessity and a methodological challenge", J Crohns Colitis, 10, pp.1096~1102 (2016)
- Ha C, "Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population", Clin Gastroenterol Hepatol, 10, pp.1002~1007 (2012)
- Kawalec P, "An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis", Arch Med Sci, 12, pp.1097~1109 (2016)
- Thorlund K, "Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy : an indirect treatment comparison metaanalysis", J Crohns Colitis, 8, pp.571~581 (2014)
- Vickers AD, "Systematic review with network meta-analysis : comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis", PLoS One, 11, pp.e0165435~ (2016)
- Bonovas S, "Systematic review with network meta-analysis : comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis", Aliment Pharmacol Ther, 47, pp.454~465 (2018)
- Singh S, "Comparison of infliximab and adalimumab in biologic-naive patients with ulcerative colitis : a nationwide danish cohort study", Clin Gastroenterol Hepatol, 15, pp.1218~1225 (2017)
- Singh S, "Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis", Aliment Pharmacol Ther, 43, pp.994~1003 (2016)
- Chen C, "Real-world pattern of biologic use in patients with inflammatory bowel disease : treatment persistence, switching, and importance of concurrent immunosuppressive therapy", Inflamm Bowel Dis, 25, pp.1417~1427 (2019)
- Pouillon L, "Treatment persistence of infliximab versus adalimumab in ulcerative colitis : a 16-year single-center experience", Inflamm Bowel Dis, 25, pp.945~954 (2019)
- Sandborn WJ, "Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States", Curr Med Res Opin, 32, pp.1233~1241 (2016)
- Satsangi J, "The Montreal classification of inflammatory bowel disease : controversies, consensus, and implications", Gut, 55, pp.749~753 (2006)
- Lewis JD, "Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis", Inflamm Bowel Dis, 14, pp.1660~1666 (2008)
- Sturm A, "ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2 : IBD scores and general principles and technical aspects", J Crohns Colitis, 13, pp.273~284 (2019)
- Turner D, "A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis", Clin Gastroenterol Hepatol, 7, pp.1081~1088 (2009)
- Peyrin-Biroulet L, "Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE) : determining therapeutic goals for treat-to-target", Am J Gastroenterol, 110, pp.1324~1338 (2015)
- Basch E, "Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events(PRO-CTCAE)", J Natl Cancer Inst, 106, pp.dju244~ (2014)
- Rubin DT, "ACG clinical guideline : ulcerative colitis in adults", Am J Gastroenterol, 114, pp.384~413 (2019)
- Harbord M, "Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2 : current management", J Crohns Colitis, 11, pp.769~784 (2017)
- Choon Jin Ooi, "Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia", Intestinal research, 17(3), pp.285~310 (2019), 대한장연구학회[DOI]
- Cramer JA, "Medication compliance and persistence : terminology and definitions", Value Health, 11, pp.44~47 (2008)
- 최창환, "Second Korean guidelines for the management of ulcerative colitis", Intestinal research, 15(1), pp.7~37 (2017), 대한장연구학회
- Danese S, "Biological agents for moderately to severely active ulcerative colitis : a systematic review and network meta-analysis", Ann Intern Med, 160, pp.704~711 (2014)
- Stidham RW, "Systematic review with network meta-analysis : the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis", Aliment Pharmacol Ther, 39, pp.660~671 (2014)
- Bank S, "Effectiveness of antitumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases", Dan Med J, 62, pp.A4994~ (2015)
- Christensen KR, "Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab : a Danish single-center cohort study", Scand J Gastroenterol, 50, pp.1018~1024 (2015)
- Rubin DT, "Response to biologic therapy in Crohn’s disease is improved with early treatment : an analysis of health claims data", Inflamm Bowel Dis, 18, pp.2225~2231 (2012)
- Sands BE, "Biomarkers of inflammation in inflammatory bowel disease", Gastroenterology, 149, pp.1275~1285 (2015)
- Mosli MH, "C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients : a systematic review and meta-analysis", Am J Gastroenterol, 110, pp.802~819 (2015)
- Solberg IC, "Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients(the IBSEN study)", Scand J Gastroenterol, 50, pp.1456~1462 (2015)
- Travis SP, "Predicting outcome in severe ulcerative colitis", Gut, 38, pp.905~910 (1996)
- Yoon JY, "Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis", Dig Dis Sci, 59, pp.829~837 (2014)
- Roblin X, "Combination of Creactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease", J Crohns Colitis, 9, pp.525~531 (2015)